EUVIMEDEUVIMED entdecken
Crossref

Three‐Stage Evolution of China's Breakthrough Therapy Drug Policy: AI‐Driven Quantitative Evidence and Global Implications

Mingming Zhai iD, Aiquan Zhang, Xinyu Li, Xiaohui Liu, Ziyi Lu, Xinyuan Zhan, Zhe Huang

The International Journal of Health Planning and Management · 2026-07 · 41 (4) · 753-767

DOI: 10.1002/hpm.70086 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The International Journal of Health Planning and Management, online erschienen am 27.05.2026. Verfasst von Mingming Zhai und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Business Administration, Shenyang Pharmaceutical University, Shenyang, China. Hauptthemen laut MEDLINE: Health Policy, Artificial Intelligence, Drug Approval. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Foundation of Liaoning Province Education Administration in China, Shenyang Pharmaceutical University Innovation and Entrepreneurship Training Program Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Many countries have accelerated the approval of innovative drugs through breakthrough therapy policies to meet public health needs. China needs to optimise its policy system to narrow the gap with international practices.

Objective

To identify shortcomings in China's breakthrough therapy policies and formulate optimization strategies via quantitative analysis of their dynamic evolution and cross‐jurisdictional comparisons.

Methods

Adopting a quantitative design, this study employs AI technologies (LDA topic modelling + time‐series deduction), combined with cross‐jurisdictional policy element matrix comparison and typical drug case analysis, to systematically analyse the evolutionary path and implementation effects of China's breakthrough therapy drug policies.

Results

Quantitative analysis of 59 policy texts (2020–2024) reveals that China's policies have undergone a three‐stage evolution: ‘approval‐driven (2020–2022)—collaborative transition (2023–2024)—ecological construction (exploratory scenario deduction after 2024)’. The core topics focus on ‘drug review’, ‘industrial innovation’, and ‘medical services’, among which ‘drug review’ and ‘industrial innovation’ form a dual‐dominant pattern. However, the persistently low intensity of the ‘medical services’ topic reflects an ecological imbalance of ‘accelerated approval—industrial innovation—lagging accessibility’. Cross‐jurisdictional comparisons show gaps in early innovation incentives, international collaboration, and medical support.

Conclusions

Based on the quantitative analysis of policy texts, this study proposes six optimization suggestions. These targeted strategies aim to address the imbalance of ‘fast approval but slow accessibility,’ support the ‘Healthy China 2030’ strategic goal, and provide references for developing countries in balancing resource allocation, accelerating research and development through the integration of artificial intelligence, and avoiding accessibility disparities via risk‐sharing mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Health PolicyArtificial IntelligenceDrug ApprovalChinaHumans

Stichwörter der Autor:innen

LDA topic modellingbreakthrough therapy drug policycross‐jurisdictional comparisonpolicy evolutionregulatory optimization

Autor:innen und Institutionen

  • School of Business Administration, Shenyang Pharmaceutical University, Shenyang, China.
  • School of Medical Devices, Shenyang Pharmaceutical University, Shenyang, China.
  • School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China.
  • School of Functional Food and Wine, Shenyang Pharmaceutical University, Shenyang, China.
  • Institution of Regulatory Science for Medical Products, Shenyang Pharmaceutical University, Shenyang, China.

ORCID-Profile: Mingming Zhai

Förderung

  • Foundation of Liaoning Province Education Administration in China
  • Shenyang Pharmaceutical University Innovation and Entrepreneurship Training Program Project

Zitieren

APA

Zhai, M., Zhang, A., Li, X., Liu, X., Lu, Z., Zhan, X., & Huang, Z. (2026). Three‐Stage Evolution of China's Breakthrough Therapy Drug Policy: AI‐Driven Quantitative Evidence and Global Implications. The International Journal of Health Planning and Management, 41(4), 753-767. https://doi.org/10.1002/hpm.70086

Vancouver

Zhai M, Zhang A, Li X, Liu X, Lu Z, Zhan X, et al. Three‐Stage Evolution of China's Breakthrough Therapy Drug Policy: AI‐Driven Quantitative Evidence and Global Implications. The International Journal of Health Planning and Management. 2026;41(4):753-767. doi:10.1002/hpm.70086

BibTeX
@article{Zhai2026,
  author = {Zhai, Mingming and Zhang, Aiquan and Li, Xinyu and Liu, Xiaohui and Lu, Ziyi and Zhan, Xinyuan and Huang, Zhe},
  title = {Three‐Stage Evolution of China's Breakthrough Therapy Drug Policy: AI‐Driven Quantitative Evidence and Global Implications},
  journal = {The International Journal of Health Planning and Management},
  year = {2026},
  volume = {41},
  number = {4},
  pages = {753--767},
  doi = {10.1002/hpm.70086}
}
Kostenlos starten →